Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...
This is a preview. Log in through your library . Abstract Background. Naturally occurring variants of human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
Science, founded by Thomas A. Edison in 1880 and published by AAAS, today ranks as the world's largest circulation general science journal. Published 51 times a year, Science is renowned for its ...
Key PointsResearch on HIV's conical capsid that began over 25 years ago led to the development of lenacapavir, the world's ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
(b. 1970) B.S., 1992, Lomonosov Moscow State University (Moscow, Russia); Ph.D., 1997, Columbia University; Postdoctoral Scientist 1997 – 1999, Columbia University ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback